Статья

C-type lectin receptors and RIG-I-like receptors: New points on the oncogenomics map

A. Kutikhin, A. Yuzhalin,
2021

The group of pattern recognition receptors includes families of Toll-like receptors, NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors. They are key sensors for a number of infectious agents, some of which are oncogenic, and they launch an immune response against them, normally promoting their eradication. Inherited variations in genes encoding these receptors and proteins and their signaling pathways may affect their function, possibly modulating cancer risk and features of cancer progression. There are numerous studies investigating the association of single nucleotide polymorphisms within or near genes encoding Toll-like receptors and NOD-like receptors, cancer risk, and features of cancer progression. However, there is an almost total absence of articles analyzing the correlation between polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors and cancer risk or progression. Nevertheless, there is some evidence supporting the hypothesis that inherited C-type lectin receptor and RIG-I-like receptor variants can be associated with increased cancer risk. Certain C-type lectin receptors and RIG-I-like receptors recognize pathogen-associated molecular patterns of potentially oncogenic infectious agents, and certain polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors may have functional consequences at the molecular level that can lead to association of such single nucleotide polymorphisms with risk or progression of some diseases that may modulate cancer risk, so these gene polymorphisms may affect cancer risk indirectly. Polymorphisms of genes encoding C-type lectin receptors and RIG-I-like receptors thereby may be correlated with a risk of lung, oral, esophageal, gastric, colorectal, and liver cancer, as well as nasopharyngeal carcinoma, glioblastoma, multiple myeloma, and lymphoma. The list of the most promising polymorphisms for oncogenomic investigations may include rs1926736, rs2478577, rs2437257, rs691005, rs2287886, rs735239, rs4804803, rs16910526, rs36055726, rs11795404, and rs10813831. © 2012 Kutikhin and Yuzhalin, publisher and licensee Dove Medical Press Ltd.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • A. Kutikhin
    Department of Epidemiology, Kemerovo State Medical Academy, Darvina Street 2-9, Kemerovo 650025, Russian Federation
  • A. Yuzhalin
Название журнала
  • Cancer Management and Research
Том
  • 4
Выпуск
  • 1
Страницы
  • 39-53
Ключевые слова
  • C type lectin receptor; CD205 receptor; CD206 receptor; CD207 receptor; CD209 antigen; dectin 1; dectin 2; langerin; lectin receptor; mannose receptor; nucleotide binding oligomerization domain like receptor; protein CLEC13B; protein CLEC13D; protein CLEC1B; protein CLEC4A; protein CLEC4E; protein CLEC4K; protein CLEC4L; protein DEC 205; retinoic acid inducible protein I; toll like receptor; unclassified drug; article; cancer growth; cancer risk; carcinogenicity; colorectal cancer; esophagus cancer; genetic association; genetic variability; glioblastoma; human; liver cancer; lung cancer; lymphoma; mouth cancer; multiple myeloma; nasopharynx carcinoma; protein expression; protein function; single nucleotide polymorphism; stomach cancer
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus